Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
Authors:
Open Access
- 20 January 2023
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 10 (2) , 463-476
Abstract
Introduction We sought to identify and compare treatment response groups based on individual patient responses (rather than group mean response) over time on the Clinical Disease Activity Index (CDAI) for rheumatoid arthritis (RA), in patients treated with baricitinib 4-mg in 4 phase 3 studies. Methods Trajectory subgroups were identified within each study using growth mixture modeling. Following grouping, baseline characteristics and disease measures were summarized and compared. Results In each study, three response trajectories were identified. In the three studies of patients naïve to biological disease-modifying anti-rheumatic drugs (bDMARDs) patients had, on average, high disease activity, as measured by CDAI. In these studies, a group of rapid responders (65–71% of patients) had the lowest baseline CDAI scores and achieved mean CDAI ≤ 10 by week 16. Gradual responders (10–17%) had higher baseline CDAI, but generally achieved low disease activity (CDAI ≤ 10) by week 24. A group of partial responders (18–22%) had higher baseline CDAI and did not achieve mean CDAI ≤ 10. In bDMARD-experienced patients, the subgroups were rapid responders, who achieved mean CDAI ≤ 10 (42% of patients); partial responders, with mean CDAI decrease of ~ 15 points from baseline (42% of patients); and limited responders (15% of patients). Changes in modified total sharp score (mTSS; assessed only in biologic-naïve patients) were below the smallest detectable difference at 24/52 weeks for > 90% of patients in each group, excepting partial responders in RA-BEGIN (≥ 75% no detectable change). Conclusion In patients receiving baricitinib 4-mg, lower baseline CDAI was generally associated with rapid response, while higher baseline CDAI scores were generally seen for patients who either reached treatment targets more gradually, or who had a partial or limited response. Maintenance of response was observed with continued baricitinib treatment in all response groups and generally included maintenance of mTSS.Keywords
Funding Information
- Eli Lilly and Company
This publication has 17 references indexed in Scilit:
- Baricitinib in Patients with Refractory Rheumatoid ArthritisNew England Journal of Medicine, 2016
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnnals of the Rheumatic Diseases, 2016
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care & Research, 2015
- Biologic efficacy optimization—a step towards personalized medicineRheumatology, 2015
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateAnnals of the Rheumatic Diseases, 2015
- Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010Annals of the Rheumatic Diseases, 2015
- Distinct Trajectories of Disease Activity Over the First Year in Early Rheumatoid Arthritis Patients Following a Treat‐to‐Target StrategyArthritis Care & Research, 2013
- Growth mixture models in longitudinal researchAStA Advances in Statistical Analysis, 2011
- Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity scoreArthritis Research & Therapy, 2005
- Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or changeAnnals of the Rheumatic Diseases, 2005